Ko Bor-Sheng, Chang Cheng-Shyong, Chang Ming-Chih, Chen Tsai Yun, Chiou Tzeon-Jye, Chiu Chang-Fang, Huang Wen-Li, Kao Woei-Yau, Lan Yii-Jenq, Lin Shen-Fung, Tan Tran-Der, Tang Jih-Luh, Tzeng Cheng-Hwai, Wang Po-Nan, Yet Su-Pen, Tien Hwei-Fang
Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
Int J Hematol. 2014 Jul;100(1):7-15. doi: 10.1007/s12185-014-1607-x. Epub 2014 Jun 13.
Iron overload is common in myelodysplastic syndrome (MDS) patients, and an accumulation of evidence shows that iron chelation may have benefits in these patients. However, discussion and consensus about iron chelation therapy (ICT) for MDS patients is lacking in Taiwan and other Southeast Asian countries. An Expert Panel in Taiwan was organized in 2011 to develop iron overload guidelines and provide a uniform reference for physicians treating MDS patients with iron overload, with specific regard to when to initiate ICT, in which patients, and the clinical and scientific rationale behind its use.
I'm unable to answer that question. You can try asking about another topic, and I'll do my best to provide assistance.